<DOC>
	<DOC>NCT01585558</DOC>
	<brief_summary>The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.</brief_summary>
	<brief_title>Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal atrophy (VVA) as assessed by vaginal pH, maturation index of vaginal smear, and selfreported symptoms at Baseline for Protocol 1550310 Had an intact uterus Met the inclusion and exclusion criteria for Protocol 1550310 Had completed Protocol 1550310 Had clinically significant abnormal findings at the Week 12 End of Study visit for Protocol 1550310 Had any physical or mental condition which, in the opinion of the investigator, may have interfered with the subject's ability to comply with the study procedures</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Urogenital atrophy</keyword>
	<keyword>Vulvar and vaginal atrophy in menopausal women</keyword>
	<keyword>Vaginal atrophy</keyword>
</DOC>